Background: Bright Light Therapy (BLT) is an effective treatment for various mood disorders, but challenges remain in optimizing its real-world administration, predicting individual responses, and understanding its mechanisms. Methods: This multicenter randomized controlled trial will enroll 231 patients with unipolar or bipolar depression, all currently experiencing a depressive episode. Participants will be randomized to one of three BLT interventions: (1) traditional home-based BLT, (2) BLT administered in the LightCafé—a novel setting promoting social interaction and lifestyle support, or (3) LightCafé BLT with personalized timing of both light and darkness by adding the use of blue light blocking glasses. The treatment duration will range from one to three weeks, based on preset definitions of participant’s response. The primary outcome is the change in depressive symptoms, assessed by a blinded rater. Secondary outcomes include subjective and objective sleep measures, circadian rhythm parameters from melatonin patterns and actigraphy, and functional outcomes. Change processes will be assessed using ecological momentary assessments of daily affect and energy levels, light exposure sensors, and via brain imaging. Discussion: This trial is the first to directly compare different BLT administration models, including a LightCafé setting. It aims to identify predictors of BLT response, investigate chronobiological and neurobiological mechanisms, and provide insights to optimize BLT for diverse patient populations. The results will inform clinical guidelines and enhance BLT's accessibility and effectiveness. Trial registration: Registered on July 14, 2023, at clinicaltrials.gov under number NCT05958940.
The interplay between sleep, light exposure, and circadian rhythms is critical for health, yet it remains inadequately described in the everyday lives of parents with young infants. Prior work has focused mainly on mothers, the early postpartum period, and short-term assessments, leaving a limited understanding of everyday parental ecologies. To address these gaps, we conducted a 2-week observation study in both mothers and fathers of infants aged 3–9 months, simultaneously measuring sleep and light exposure using wearable actigraphy and light sensors alongside sleep diaries. Our descriptive approach aimed to characterize real-life patterns of sleep and light, quantify their variability across nights and individuals, and explore differences by infant age, parental role, and contextual factors. We found that while sleep duration was generally adequate, nights were frequently fragmented, with multiple awakenings and substantial variability across individuals and nights. Light exposure during waking hours was predominantly dim, and brief exposures to light during sleep episodes were common. Seasonal variation, infant sleep location, and caregiving roles may have shaped sleep-light patterns. These findings highlight the complexity and heterogeneity of sleep and light ecologies in early parenthood, and underscore the value of wearable monitoring and descriptive profiling for informing circadian-aware interventions.
Sleep disturbance is a central feature of depression and a proposed pathway through which Bright-Light Therapy (BLT) exerts antidepressant effects. However, little is known about how sleep reorganises day by day during BLT or whether these dynamics relate to symptom improvement. We analysed daily sleep diaries from 66 patients with depression undergoing three weeks of BLT in routine outpatient care. Generalised Additive Mixed Models characterised daily trajectories in sleep timing, continuity, duration, and Subjective Sleep Quality, and weekly changes in sleep regularity were assessed using Root Mean Square of the Successive Differences. Structural Equation Modelling examined whether within-person deviations in sleep parameters mediated changes in depressive symptoms. Sleep timing showed gradual adjustment across treatment, with a progressive 48 min advance in weekday sleep onset. Sleep regularity improved from Week 1 to Week 2 before partially reversing, and the probability of nocturnal awakenings followed a non-linear trajectory. Other sleep parameters showed weaker directional trends. Improvements in Subjective Sleep Quality accounted for a modest portion of the association between treatment progression and reductions in depressive symptoms, whereas changes in sleep timing and regularity were not associated with symptom change. These findings indicate that sleep reorganises gradually during outpatient BLT, with different sleep dimensions evolving on distinct timescales and Subjective Sleep Quality emerging as one observable component linked to symptom improvement. More broadly, the results highlight the value of day-to-day modelling for understanding sleep–mood dynamics during real-world chronotherapy.